OSLO, Norway, Nov. 21, 2019 /PRNewswire/ --
Oslo, Norway, 21 November 2019
FINANCIAL YEAR 2019
27.02.2020 - Quarterly Report - Q4
FINANCIAL YEAR 2020
17.04.2020 - Annual General Meeting
26.05.2020 - Quarterly Report - Q1
27.08.2020 - Half-yearly Report - Q2
19.11.2020 - Quarterly Report - Q3
The dates are subject to change. The time and location of the presentations will be announced in due time.
This information is published pursuant to the requirements set out in the Continuing obligations.
For further information, please contact:
IR enquiries
Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin in core markets.
Further information can be found at www.nordicnanovector.com.
This information is subject to a duty of disclosure pursuant to the Securities Trading Act, Sections 4-2 and 5-12 / Oslo Stock Exchange's Continuing Obligations, Section 3.2.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa---financial-calendar,c2970226
